FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010411643> ?p ?o ?g. }

• W2010411643 endingPage "1061" @default.
• W2010411643 startingPage "1061" @default.
• W2010411643 abstract "Since 1997, guidelines for the care of HIV-1-infected individuals stated that women should receive optimal antiretroviral therapy regardless of their reproductive status [1]. Highly active antiretroviral therapy (HAART) can effectively reduce viral load and limit the evolution of viral resistance. When used during pregnancy, HAART has the theoretical potential of reducing the risk of perinatal transmission [2]. However, information on the pharmacokinetics of these regimens during pregnancy is limited, especially concerning protease inhibitors (PI) such as indinavir (IDV). The need for ongoing clinical trials to evaluate the safety, tolerance, and pharmacokinetics of HAART in this patient population is clear [3]. Pregnancy produces unique physiological changes, including alterations in hepatic and placental drug metabolizing systems involving the cytochrome P450 isoenzymes, which affect drug disposition. Elevated levels of endogenous glucocorticoids, peaking during the third trimester, may induce CYP3A4 [4], the predominant enzyme responsible for the metabolism of IDV and other PI [5]. Our group further demonstrated the induction of CYP3A4 during pregnancy (unpublished data). Consequently, pregnancy may cause reduced PI plasma concentrations, resulting in sub-therapeutic exposure. We describe two cases of HIV-positive women followed from their second and third trimesters of pregnancy up to 3 months postpartum. Both patients were treated with HAART including IDV. The first case is a 35-year-old woman, stabilized with lamivudine (150 mg twice a day), stavudine (20 mg twice a day), and IDV (800 mg every 8 h) upon enrolment. The viral load and CD4 cell count at 19 weeks' estimated gestational age (EGA), one month before enrolment, were 65 copies/ml (ultrasensitive modification of Roche Amplicor HIV-1, Roche, Nutley, NJ, USA) and 924 cells/mm3, respectively. Her regimen remained unchanged during pregnancy and her viral load increased to 390 copies/ml at the third trimester (week 33), decreasing to 215 copies/ml postpartum. She delivered an HIV-uninfected infant in March 1999. Serial pharmokinetic plasma samples (0–8 h) were collected at 21, 33 and 38 weeks EGA, and 9 weeks postpartum to estimate IDV exposures. The urinary 6-beta-hydroxycortisol : cortisol ratio was also determined from urine collected pre-dosing to assess the activity of CYP3A [6], which catalyses the conversion of endogenous cortisol to 6-beta-hydroxycortisol. The second case was a 36-year-old woman enrolled at 32 weeks' EGA. She had been receiving zidovudine (300 mg twice a day), lamivudine (150 mg twice a day), and IDV (800 mg every 8 h) since February 1997. Her viral load was undetectable (< 500 copies/ml) at third trimester and postpartum visits. She delivered an HIV-uninfected infant in July 1998. Serial pharmacokinetic plasma samples were collected at week 34 and 12 weeks' postpartum. Liver and kidney function for both women remained normal throughout the observation period and no additional drugs known to affect CYP3A4 were received. The pharmacokinetic parameters of IDV and the urinary 6-beta-hydroxycortisol : cortisol ratio are summarized in Table 1. Plasma concentrations of IDV were determined by liquid chromatography tandem mass-spectrometry assay [7]. Urinary 6-beta-hydroxycortisol and cortisol were determined by high performance liquid chromatography assay [6], modified for application to samples from pregnant women. A marked difference was observed in plasma IDV area under the curve (AUC0−−8) between the third trimester and postpartum in both cases, despite an unchanged IDV dose. Although the AUC0−−8 from postpartum visits corresponded to reported values (19 300–42 098 nM × h) (CrixivanTM product information), AUC0−−8 at third trimester visits were reduced from the postpartum values by 63 and 86% in cases 1 and 2, respectively. Similar reductions were observed in the maximum plasma concentrations. The observed decrease in plasma concentrations of IDV could be attributed to the increased clearance and volume of distribution during the third trimester. The change in IDV clearance appeared to correspond to an increase in the urinary 6-beta-hydroxycortisol ratio, suggesting that CYP3A4 activity is enhanced during late pregnancy. Interestingly, a third case involving a women at 31 weeks' EGA on IDV (800 mg q12h) and ritonavir (200 mg q12h), a potent CYP inhibitor, produced an IDV AUC0−−12 five times that measured in women on IDV alone at similar weeks' EGA. Reduced absorption, placental drug passage, and protein binding changes may also contribute to lower plasma IDV concentrations.Table 1: Pharmacokinetic parameters of indinavir and urinary 6-beta-hydroxycortisol : cortisol ratio. These cases suggest that pregnant women may be exposed to sub-therapeutic drug levels during the later stages of pregnancy. This may require doses of PI higher than standard regimens or the use of dual PI including ritonavir. Although maternal viral load remained low during the course of our observations, long-term clinical outcomes remain uncertain. Anecdotal reports of viral breakthrough, while taking HAART, during the postpartum period remains a serious concern in new mothers. The striking pharmokinetic results of these two cases may provide a preliminary explanation for these reports. Further study is required to define the pharmokinetic changes during pregnancy to optimize maternal health and the long-term use of HAART. Sandra Hayashia Karen Beckermanb Masato Hommac Bradley W. Kosela Francesca T. Aweekaa" @default.
• W2010411643 created "2016-06-24" @default.
• W2010411643 creator A5028526784 @default.
• W2010411643 creator A5055858204 @default.
• W2010411643 creator A5063298724 @default.
• W2010411643 creator A5084498942 @default.
• W2010411643 creator A5085186723 @default.
• W2010411643 date "2000-05-01" @default.
• W2010411643 modified "2023-10-16" @default.
• W2010411643 title "Pharmacokinetics of indinavir in HIV-positive pregnant women" @default.
• W2010411643 cites W1978358504 @default.
• W2010411643 cites W2053623537 @default.
• W2010411643 cites W2147459171 @default.
• W2010411643 cites W2335180953 @default.
• W2010411643 doi "https://doi.org/10.1097/00002030-200005260-00020" @default.
• W2010411643 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10853990" @default.
• W2010411643 hasPublicationYear "2000" @default.
• W2010411643 type Work @default.
• W2010411643 sameAs 2010411643 @default.
• W2010411643 citedByCount "30" @default.
• W2010411643 countsByYear W20104116432012 @default.
• W2010411643 countsByYear W20104116432013 @default.
• W2010411643 countsByYear W20104116432020 @default.
• W2010411643 countsByYear W20104116432022 @default.
• W2010411643 crossrefType "journal-article" @default.
• W2010411643 hasAuthorship W2010411643A5028526784 @default.
• W2010411643 hasAuthorship W2010411643A5055858204 @default.
• W2010411643 hasAuthorship W2010411643A5063298724 @default.
• W2010411643 hasAuthorship W2010411643A5084498942 @default.
• W2010411643 hasAuthorship W2010411643A5085186723 @default.
• W2010411643 hasBestOaLocation W20104116431 @default.
• W2010411643 hasConcept C112705442 @default.
• W2010411643 hasConcept C126322002 @default.
• W2010411643 hasConcept C142462285 @default.
• W2010411643 hasConcept C203014093 @default.
• W2010411643 hasConcept C2522874641 @default.
• W2010411643 hasConcept C2777210460 @default.
• W2010411643 hasConcept C2777869810 @default.
• W2010411643 hasConcept C2779234561 @default.
• W2010411643 hasConcept C2779889181 @default.
• W2010411643 hasConcept C2780593183 @default.
• W2010411643 hasConcept C2908647359 @default.
• W2010411643 hasConcept C2993143319 @default.
• W2010411643 hasConcept C3013748606 @default.
• W2010411643 hasConcept C42407357 @default.
• W2010411643 hasConcept C54355233 @default.
• W2010411643 hasConcept C71924100 @default.
• W2010411643 hasConcept C86803240 @default.
• W2010411643 hasConcept C98274493 @default.
• W2010411643 hasConcept C99454951 @default.
• W2010411643 hasConceptScore W2010411643C112705442 @default.
• W2010411643 hasConceptScore W2010411643C126322002 @default.
• W2010411643 hasConceptScore W2010411643C142462285 @default.
• W2010411643 hasConceptScore W2010411643C203014093 @default.
• W2010411643 hasConceptScore W2010411643C2522874641 @default.
• W2010411643 hasConceptScore W2010411643C2777210460 @default.
• W2010411643 hasConceptScore W2010411643C2777869810 @default.
• W2010411643 hasConceptScore W2010411643C2779234561 @default.
• W2010411643 hasConceptScore W2010411643C2779889181 @default.
• W2010411643 hasConceptScore W2010411643C2780593183 @default.
• W2010411643 hasConceptScore W2010411643C2908647359 @default.
• W2010411643 hasConceptScore W2010411643C2993143319 @default.
• W2010411643 hasConceptScore W2010411643C3013748606 @default.
• W2010411643 hasConceptScore W2010411643C42407357 @default.
• W2010411643 hasConceptScore W2010411643C54355233 @default.
• W2010411643 hasConceptScore W2010411643C71924100 @default.
• W2010411643 hasConceptScore W2010411643C86803240 @default.
• W2010411643 hasConceptScore W2010411643C98274493 @default.
• W2010411643 hasConceptScore W2010411643C99454951 @default.
• W2010411643 hasIssue "8" @default.
• W2010411643 hasLocation W20104116431 @default.
• W2010411643 hasLocation W20104116432 @default.
• W2010411643 hasLocation W20104116433 @default.
• W2010411643 hasOpenAccess W2010411643 @default.
• W2010411643 hasPrimaryLocation W20104116431 @default.
• W2010411643 hasRelatedWork W1491591405 @default.
• W2010411643 hasRelatedWork W1820255751 @default.
• W2010411643 hasRelatedWork W2022087185 @default.
• W2010411643 hasRelatedWork W2066184048 @default.
• W2010411643 hasRelatedWork W2070504323 @default.
• W2010411643 hasRelatedWork W2316412239 @default.
• W2010411643 hasRelatedWork W2317995319 @default.
• W2010411643 hasRelatedWork W2419128347 @default.
• W2010411643 hasRelatedWork W2914058108 @default.
• W2010411643 hasRelatedWork W4297935455 @default.
• W2010411643 hasVolume "14" @default.
• W2010411643 isParatext "false" @default.
• W2010411643 isRetracted "false" @default.
• W2010411643 magId "2010411643" @default.
• W2010411643 workType "article" @default.